548 related articles for article (PubMed ID: 24679996)
21. Fronto-Cerebellar Neurometabolite Alterations After Methylphenidate in Children and Adolescents With ADHD: A Proton Magnetic Resonance Spectroscopy Study.
Bakhshi S; Tehrani-Doost M; Batouli SAH
J Atten Disord; 2023 Feb; 27(4):410-422. PubMed ID: 36635897
[TBL] [Abstract][Full Text] [Related]
22. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
23. Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
Ruocco LA; Carnevale UA; Treno C; Sadile AG; Melisi D; Arra C; Ibba M; Schirru C; Carboni E
Behav Brain Res; 2010 Jun; 210(1):99-106. PubMed ID: 20156489
[TBL] [Abstract][Full Text] [Related]
24. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
25. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
Smith A; Cubillo A; Barrett N; Giampietro V; Simmons A; Brammer M; Rubia K
Biol Psychiatry; 2013 Oct; 74(8):615-22. PubMed ID: 23731741
[TBL] [Abstract][Full Text] [Related]
26. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
Jaworowski S; Benarroch F; Gross-Tsur V
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
[TBL] [Abstract][Full Text] [Related]
27. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
Kowalczyk OS; Cubillo AI; Smith A; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Eur Neuropsychopharmacol; 2019 Oct; 29(10):1102-1116. PubMed ID: 31358436
[TBL] [Abstract][Full Text] [Related]
28. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
[TBL] [Abstract][Full Text] [Related]
29. Striatal neuronal loss or dysfunction and choline rise in children with attention-deficit hyperactivity disorder: a 1H-magnetic resonance spectroscopy study.
Jin Z; Zang YF; Zeng YW; Zhang L; Wang YF
Neurosci Lett; 2001 Nov; 315(1-2):45-8. PubMed ID: 11711211
[TBL] [Abstract][Full Text] [Related]
30. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
31. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong J; Dilla T; Arellano J
BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
[TBL] [Abstract][Full Text] [Related]
33. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
Prasad S; Steer C
Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
[TBL] [Abstract][Full Text] [Related]
34. Update on drugs for hyperactivity in childhood.
Drug Ther Bull; 2007 May; 45(5):37-40. PubMed ID: 17536494
[TBL] [Abstract][Full Text] [Related]
35. Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate.
Fumagalli F; Cattaneo A; Caffino L; Ibba M; Racagni G; Carboni E; Gennarelli M; Riva MA
Pharmacol Res; 2010 Dec; 62(6):523-9. PubMed ID: 20691787
[TBL] [Abstract][Full Text] [Related]
36. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.
Kratz O; Studer P; Baack J; Malcherek S; Erbe K; Moll GH; Heinrich H
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):81-9. PubMed ID: 22227291
[TBL] [Abstract][Full Text] [Related]
38. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
39. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
40. Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
Heinrich H; Studer P; Moll GH; Kratz O
JAMA Psychiatry; 2013 May; 70(5):545. PubMed ID: 23636880
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
